idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Scientists have initiated a study to investigate whether dapagliflozin, an already approved drug from the SGLT2 inhibitors group, can positively affect the course of autosomal dominant polycystic kidney disease (ADPKD)
For some years now, a new and effective treatment option known as SGLT2 inhibitors has been available for patients with kidney disease. Unfortunately, not all those affected can benefit from this therapy. People with polycystic kidney disease are excluded from this, however, meaning that the efficacy and safety of this approach in polycystic kidney disease is currently unclear. Polycystic kidney disease is the most common form of genetic kidney disease and affects more than 10 million people worldwide. A team led by kidney specialist Professor Dr Roman-Ulrich Müller, Chair of Translational Nephrology, was able to raise over 3 million euros from the German Research Foundation for the first three years of a trial program, which will answer this question. Follow-up funding for the three subsequent years has already been announced. The large-scale STOP-PKD trial has now been launched in Cologne. International partner organizations are also involved in the project.
“We have reached the first decisive milestone. The first centre has now been initiated in Cologne. Over the next six to nine months, at least 26 more centres in Germany, the Netherlands, Spain, and Austria will begin the STOP-PKD study,” says Professor Müller.
The STOP-PKD study is supported and financed by the German Research Foundation (DFG). As part of the DFG proposal, the German Society of Nephrology (DGfN), the European Renal Association (ERA), and the European Rare Kidney Disease Reference Network (ERKNet) expressly endorsed conducting the study in order to research new treatment options for ADPKD. In addition, various patient organizations are supporting the study with advice and help towards patient recruitment.
Press and Communications Team:
Dr Anna Euteneuer
+49 470 1700
a.euteneuer@verw.uni-koeln.de
Press Spokesperson: Dr Elisabeth Hoffmann – e.hoffmann@verw.uni-koeln.de
Media Contact:
Professor Dr Roman-Ulrich Müller
Department II of Internal Medicine, University Hospital Cologne
+49 221 478 3439
roman-ulrich.mueller@uk-koeln.de
https://Further information:
https://stop-pkd.de/
https://www.uk-koeln.de/uniklinik-koeln/aktuelles/detailansicht/studie-zur-behan...
Merkmale dieser Pressemitteilung:
Journalisten
Medizin
überregional
Forschungsergebnisse, Forschungsprojekte
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
